UBS upgrades Regeneron stock to Buy at USD 978.00 target

Published on 10/15/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pasatru showed zero new lesions versus nine for placebo at week 84 on October 12, 2026. Regeneron stock costs EUR 699.90 on October 15, 2026.

Pipeline data and reporting date

Pasatru produced zero new lesions versus nine for placebo on October 12, 2026.
UBS set a USD 978.00 target after its October 14, 2026 upgrade.
Regeneron stock trades at EUR 699.90 at 11:16 a.m. CEST at Lang & Schwarz on October 15, 2026.
Third-quarter 2026 results are scheduled for October 30, 2026.

Aquarellmalerei eines modernen Forschungscampus mit Glastürmen am Flussufer — Regeneron Pharma US75886F1075 präsentiert eine stimmungsvolle Aquarell-Ansicht eines modernen Forschungscampus entlang eines ruhigen Flussufers, Illustration mit AI erstellt.

Regeneron (ISIN US75886F1075) received a Buy upgrade from UBS with a USD 978.00 price target on October 14, 2026, according to GuruFocus. The report linked the view to next-generation Dupixent candidates and described Regeneron as undervalued at the cited target.

Pasatru delivers a clear trial result

Regeneron said on October 12, 2026, that Pasatru produced zero new heterotopic ossification lesions in adults with fibrodysplasia ossificans progressiva during the OPTIMA trial extension, compared with nine lesions for placebo at week 84.

The result gives the pipeline a concrete clinical marker alongside the commercial base. In the second quarter of 2026, revenue reached USD 4.29 billion, while net income attributable to common shareholders was USD 1.30 billion and diluted earnings per share were USD 12.23.

What does the upgrade imply?

UBS placed its target at USD 978.00 on October 14, 2026, while the cited valuation discussion put Regeneron's market capitalization at USD 80.14 billion. The same report said next-generation Dupixent candidates could generate USD 16.00 billion in revenue by 2035, compared with a USD 13.00 billion consensus estimate, a long-range scenario rather than current revenue.

Three dated steps in the pipeline

On October 1, 2026, Regeneron highlighted ubamatamab data in advanced low-grade serous ovarian cancer. On October 6, 2026, the company presented cancer research at the European Society for Medical Oncology congress. On October 12, 2026, Pasatru data showed zero new lesions versus nine for placebo at week 84, according to Regeneron.

Next date for Regeneron investors

Regeneron will report third-quarter 2026 financial and operating results on October 30, 2026, before US financial markets open, with a conference call at 8:30 a.m. Eastern Time.

Price stays in the investor frame

Regeneron is a biotechnology company focused on discovering, developing and commercializing medicines in areas including eye diseases, cancer, inflammatory conditions and rare diseases. Its primary listing is Nasdaq under ticker REGN.

Regeneron was trading at EUR 699.90 at Lang & Schwarz on October 15, 2026 at 11:16 a.m. CEST. The quote's 52-week reference range in US dollars was USD 564.00 to USD 859.34 as of October 15, 2026, while market capitalization stood at USD 80.1 billion.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.